Petasiphenone, a phenol isolated from Cimicifuga racemosa, in vitro inhibits proliferation of the human prostate cancer cell line LNCaP.

Division of Clinical and Experimental Endocrinology, University of Göttingen, Göttingen, Germany.
Planta Medica (Impact Factor: 2.34). 02/2007; 73(2):184-7. DOI: 10.1055/s-2006-957081
Source: PubMed

ABSTRACT Extracts of Cimicifuga racemosa (L.) Nutt. (syn.: Actaea racemosa L.) (CR) inhibit the proliferation of the human prostate cancer cell line LNCaP. Recently, the phenylpropanoid ester 3,4-dihydroxyphenacyl caffeate (petasiphenone, 1) was isolated from CR. This substance is a structural homologue to petasiphenol ([3-(3,4-dihydroxyphenyl)-2-oxopropyl caffeate]), a compound produced by Petasites japonicus Sieb. & Zucc. which inhibits the growth of various human leukemia cell lines. Because of the structural similarity, we examined whether 1 affects the proliferation of LNCaP cells and the secretion of prostate-specific antigen (PSA). Under basal conditions as well as under co-incubation with 10 nM estradiol [E2 or 1 nM dihydrotestosterone (DHT)], 1 dose-dependently inhibited proliferation of LNCaP cells while PSA release per cell was not altered. We report for the first time that a defined compound isolated from CR inhibits the growth of the human prostate cancer cells LNCaP.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Two new cycloartenol triterpene saponins, 7,8,16,17-tetrahydro-23R,24R-O-acetyl-hydroshengmanol-3-O-β-d-galactopyranoside (1), 16,17-didehydro-23R,24R-O-acetyl-hydroshengmanol-3-O-β-d-galactopyranoside (2), were isolated from the ethyl acetate soluble fraction of Cimicifuga simplex Wormsk. Their structures were established by detailed spectroscopic analysis, including extensive 2D NMR data. This is the first time to report 16,17-double bond type glycosidesaponin from Cimicifuga species. Their immunosuppressive activities were also carried out by ConA-stimulated T splenocyte proliferation assay in vitro.
    Phytochemistry Letters 05/2014; · 1.54 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The cardinal climacteric symptoms of hot flushes and night sweats affect 24-93% of all women during the physiological transition from reproductive to post-reproductive life. Though efficacious, hormonal therapy and partial oestrogenic compounds are linked to a significant increase in breast cancer. Non-hormonal treatments are thus greatly appreciated. This systematic review of published hormonal and non-hormonal treatments for climacteric, and breast and prostate cancer-associated hot flushes, examines clinical efficacy and therapy-related cancer risk modulation. A PubMed search included literature up to June 19, 2014 without limits for initial dates or language, with the search terms, (hot flush* OR hot flash*) AND (clinical trial* OR clinical stud*) AND (randomi* OR observational) NOT review). Retrieved references identified further papers. The focus was on hot flushes; other symptoms (night sweats, irritability, etc.) were not specifically screened. Included were some 610 clinical studies where a measured effect of the intervention, intensity and severity were documented, and where patients received treatment of pharmaceutical quality. Only 147 of these references described studies with alternative non-hormonal treatments in post-menopausal women and in breast and prostate cancer survivors; these results are presented in Additional file 1. The most effective hot flush treatment is oestrogenic hormones, or a combination of oestrogen and progestins, though benefits are partially outweighed by a significantly increased risk for breast cancer development. This review illustrates that certain non-hormonal treatments, including selective serotonin reuptake inhibitors, gabapentin/pregabalin, and Cimicifuga racemosa extracts, show a positive risk-benefit ratio. Key pointsSeveral non-hormonal alternatives to hormonal therapy have been established and registered for the treatment of vasomotor climacteric symptoms in peri- and post-menopausal women.There are indications that non-hormonal treatments are useful alternatives in patients with a history of breast and prostate cancer. However, confirmation by larger clinical trials is required.
    SpringerPlus 12/2015; 4(1).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Black cohosh (Actaea racemosa L.), Ranunculaceae, thrives in temperate climates east of the Mississippi River in the USA. It is economically important to the Appalachian region where it is wild harvested, but it has resisted most efforts at deliberate cultivation. Black cohosh has been used for many centuries both in Europe and in the US (by indigenous people and subsequent Caucasian medical practitioners), most notably for indications of premenstrual syndrome (PMS), menstrual pain and cramping. To highlight black cohosh as an example in which disregard for the ethnobotanical and ethnopharmacologic usages of a plant has perhaps hindered modern scientific attempts to understand the mechanism of action of its bioactive phytochemicals, and ascribe cause to effect. Research on its mode of action has historically focused on its presumed hormonal (phytoestrogenic) activity, but very recent work suggests that it may in fact be acting as an antinociceptive agent. Re-examination of some of the writings of 19th and 20th century physicians and folk literature suggests that this mode of action may have been overlooked in modern experimentalists' in vitro and animal studies and in the very few well conducted human trials to date. The common folk perception of this plant as a "remedy for female problems" may thus require revision, as it may possess more general analgesic properties. In the broader context, ethnopharmacologic indications for other herbal remedies must be revisited in light of the explosion in understanding of mechanisms of action of small molecule effectors of which actein and cimicifugoside (from black cohosh) are only two examples.
    Journal of ethnopharmacology 04/2012; 141(3):775-9. · 2.32 Impact Factor


Available from
May 20, 2014